Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 4/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128173 | 1.00 | ATM (0.44) | ATMHCAR2CES2FDPSGGPS1 | |
| SCHEMBL128175 | 0.93 | HCAR2 (0.53) | ATMHCAR2 | |
| SCHEMBL128174 | 0.93 | HCAR2 (0.53) | ATMHCAR2 | |
| SCHEMBL1301122 | 0.93 | HCAR2 (0.53) | ATMHCAR2 | |
| SCHEMBL7502204 | 0.90 | HCAR2 (0.46) | ATMHCAR2CES2FDPSGGPS1 | |
| SCHEMBL4934050 | 0.87 | CES2 (0.35) | ATMHCAR2CES2FDPSGGPS1 | |
| SCHEMBL3247328 | 0.85 | TSHR (0.47) | ATMHCAR2CES2SMPD1HPGD | |
| SCHEMBL7502219 | 0.84 | HCAR2 (0.57) | ATMHCAR2 | |
| SCHEMBL7502212 | 0.84 | HCAR2 (0.57) | ATMHCAR2 | |
| SCHEMBL141053 | 0.82 | MEN1 (0.40) | ATMCES2FDPSGGPS1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563482-A2 | LOTION COMPOSITION FOR WET WIPES | The Procter & Gamble Company (US) | 2013-03-06 | — | — | EP | claimed |
| WO-2011139492-A2 | LOTION COMPOSITION FOR WET WIPES | THE PROCTER & GAMBLE COMPANY (US) | 2011-11-10 | — | — | WO | claimed |
| US-20110268777-A1 | Lotion Composition for Wet Wipes | PROCTER & GAMBLE COMPANY, THE | 2011-11-03 | — | — | US | claimed |
| US-12552129-B2 | Nonwoven water-soluble composite structure | MONOSOL, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250249021-A1 | Compositions Comprising 5-Cholesten-3, 25-Diol, 3-Sulfate (25HC3S) or Pharmaceutically Acceptable Salt Thereof And at Least One Cyclic Oligosaccharide | JPMORGAN CHASE BANK, N.A. | 2025-08-07 | — | — | US | disclosed |
| EP-4382083-B1 | NONWOVEN WATER-SOLUBLE COMPOSITE STRUCTURE | MONOSOL LLC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12226423-B2 | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240401246-A1 | WATER SOLUBLE FIBERS WITH POST PROCESS MODIFICATIONS AND ARTICLES CONTAINING SAME | MONOSOL, LLC | 2024-12-05 | — | — | US | disclosed |
| EP-4442872-A2 | WATER SOLUBLE FIBERS WITH POST PROCESS MODIFICATIONS AND ARTICLES CONTAINING SAME | Monosol, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12060658-B2 | Water soluble fibers with post process modifications and articles containing same | MONOSOL, LLC (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4382083-A2 | NONWOVEN WATER-SOLUBLE COMPOSITE STRUCTURE | Monosol, LLC (US) | 2024-06-12 | — | — | EP | disclosed |
| US-5216089-A | Includes modifier comprising of alpha-beta-unsaturated carboxylic acid derivatives | GENERAL ELECTRIC COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
| US-5214109-A | Modified polyphenylene ether resins having improved processability and oxidative stability | GENERAL ELECTRIC COMPANY (US) | 1993-05-25 | — | — | US | disclosed |
| EP-0266617-B1 | MODIFIED POLYPHENYLENE ETHER RESINS HAVING IMPROVED FOAMABILITY AND METHODS OF MAKING THE SAME | GENERAL ELECTRIC COMPANY (US) | 1992-07-15 | — | — | EP | disclosed |
| EP-0125911-B1 | PROCESS FOR PRODUCTION OF OLEFIN POLYMER OR COPOLYMER | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-09-20 | — | — | EP | disclosed |
| EP-0266617-A2 | Modified polyphenylene ether resins having improved foamability and methods of making the same | GENERAL ELECTRIC COMPANY (US) | 1988-05-11 | — | — | EP | disclosed |
| EP-0257486-A1 | Modified polyphenylene ether resins having improved processability and oxidative stability | GENERAL ELECTRIC COMPANY (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4728674-A | ALPHA, BETA-UNSATURATED CARBOXYLIC ACID DERIVATIVE | GENERAL ELECTRIC COMPANY (US) | 1988-03-01 | — | — | US | disclosed |
| US-4684669-A | LIGHTWEIGHT | GENERAL ELECTRIC COMPANY (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0125911-A1 | Process for production of olefin polymer or copolymer | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250249021-A1 | Compositions Comprising 5-Cholesten-3, 25-Diol, 3-Sulfate (25HC3S) or Pharmaceutically Acceptable Salt Thereof And at Least One Cyclic Oligosaccharide | CYP46A1, HSD3B1, HSD3B2 | ATM 4747/4885HCAR2 1218/4885CES2 1794/4885 |
| US-12552129-B2 | Nonwoven water-soluble composite structure | SMARCD2, BRWD1, PWWP2B | ATM 494/4885HCAR2 4475/4885CES2 680/4885 |
| US-12226423-B2 | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide | CYP46A1, HSD3B1, HSD3B2 | ATM 4747/4885HCAR2 1218/4885CES2 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.